HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (4- (2- (diethylamino)ethoxy)phenyl)- N- (2,4- difluorobenzyl)- 5- fluoropyrimidin- 4- amine

structure in first source

Also Known As:

RS 1748; RS-1748; RS1748

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - 2-(4-(2-(diethylamino)ethoxy)phenyl)-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine: 1

Experts

1.	Etori, Maki: 1 article (01/2010)
2.	Fukuda, Takeshi: 1 article (01/2010)
3.	Kawase, Yumi: 1 article (01/2010)
4.	Kuribayashi, Takeshi: 1 article (01/2010)
5.	Nakagami, Yasuhiro: 1 article (01/2010)
6.	Nara, Futoshi: 1 article (01/2010)
7.	Nosaka, Emi: 1 article (01/2010)
8.	Takagi, Nana: 1 article (01/2010)
9.	Takahashi, Sakiko: 1 article (01/2010)
10.	Yamashita, Makoto: 1 article (01/2010)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2010 - "Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg. These results indicate that RS-1748 would be a promising lead compound for developing a therapeutic agent against asthma." 01/01/2010 - "RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs."
2.	Asthma (Bronchial Asthma) 01/01/2010 - "Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg. These results indicate that RS-1748 would be a promising lead compound for developing a therapeutic agent against asthma."

Related Drugs and Biologics

1.	CCR4 Receptors
2.	Ovalbumin